Weekly Recap | INSILICO -0.47%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:31 AM03696-8.55%
Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug DiscoveryPUBT·Nov 13, 2026 at 08:36 AM03696-8.55%002793-5.39%
Weekly Recap | INSILICO +0.54%, most brokers rate it buyWeekly Review·Nov 7, 2026 at 06:04 AM03696-8.55%
Insilico Medicine plans share buyback of up to HK$ 500 millionPUBT·Oct 30, 2026 at 12:16 AM03696-8.55%
Insilico Medicine Grants 108,423 Restricted Share Units to EmployeesPUBT·Oct 29, 2026 at 12:12 PM03696-8.55%
Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma TrialPUBT·Oct 26, 2026 at 01:02 PM03696-8.55%
Insilico Medicine drops 2% in Hong Kong tradingHK Stock Market Update·Oct 26, 2026 at 01:36 AM03696-8.55%
Weekly Recap | INSILICO -6.8%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 05:30 AM03696-8.55%
Insilico Medicine falls 5% as AI drug discovery sector weakensHK Stock Market Update·Oct 23, 2026 at 01:40 AM03696-8.55%